Contact Us
800.227.0627

Locked Nucleic Acid - LNA - TEW

 
Print Print
Please select subject area:
Locked Nucleic Acid - LNA
Biosyn
Highly nuclease resistance and thermodynamically stable 2′-O,4′-C-Ethylene-bridged Nucleic Acid (ENA) as a promising candidate for antisense therapy
01/12/2024
Biosyn
Invader Probes Allow Selective Genomic Target Detection
10/13/2022
Biosyn
How do Oligonucleotide Drugs cross the Blood Brain Barrier?
09/15/2021
Biosyn
Sugar modifications for gene silencing using siRNA
03/26/2021
Biosyn
Tumor drug penetration measurement reveals limited distribution of fluor-conjugated Herceptin antibody in a mouse breast cancer model
03/08/2021
Biosyn
Fatty acid conjugated BNA antisense oligonucleotides exhibit enhanced uptake into muscle
03/04/2021
Biosyn
FDA approves second RNA interference-inducing siRNA oligonucleotide drug for treating acute hepatic porphyria, raising the prospect for cancer therapy
02/23/2021
Biosyn
Potential use of mRNA encoding scFv recognizing amyloid-beta peptide to treat Alzheimer's disease
02/11/2021
Biosyn
Argonaute-2 can bind metabolic stable siRNAs
02/03/2021
Biosyn
Applying mRNA based technology to express a surplus of decoy ACE2 receptors to prevent COVID-19 infection
01/29/2021
Biosyn
Diagnosing the androgen receptor splicing variant ARv7: a biomarker of resistance to anti-hormone therapy for advanced stage metastatic prostate cancer in the era of COVID-19
12/21/2020
Biosyn
The potential use of DNA or mRNA-based vaccines incorporating modified nucleotides to suppress cancer or COVID-19 pandemic
12/01/2020
Biosyn
BNAs for Duplex and Triplex Formation
11/20/2020
Biosyn
Evaluating the efficacy of RT-PCR in assessing infectivity, accuracy of death rate and counts, and the treatments for cancer patients in the era of COVID-19
09/25/2020
Biosyn
Liquid biopsies containing circulating tumor DNA (ctDNA) for diagnosing biomarkers for early detection, metastatic recurrence or targeted therapy: implication for COVID-19 diagnosis
08/21/2020
123
imgscroll